Fig. 4.

Percentage of responders with anti-Spike antibodies 1 month after the second and 1 month after the third dose of an anti-severe acute respiratory syndrome coronavirus 2 vaccine in participants from the ANRS0001S COV-POPART cohort who received three doses as a primary vaccination regimen. The vertical bars indicate 95% CI. HCT, hematopoietic stem cell transplant; HIV, human immunodeficiency virus; IRD, inflammatory rheumatic disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; SAD, systemic autoimmune disease; SOT, solid organs transplanted.